Publications by authors named "H Mizugaki"
Critical limb ischemia (CLI) is the most advanced stage of peripheral arterial disease, posing a high risk of mortality. Sphingomyelin, a sphingolipid synthesized by sphingomyelin synthases (SMSs) 1 and 2, plays an essential role in signal transduction as a component of lipid rafts. However, the role of sphingomyelin in the inflammation of ischemic skeletal muscles remains unclear.
View Article and Find Full Text PDFBackground: In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed to determine whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected.
Methods: We performed a retrospective multicenter study (sub-analysis of the HOT/NJLCG2001 trial) of 299 patients with NSCLC with high PD-L1 expression who received MONO or COMB as the first-line treatment between December 2018 and January 2020. We selected patients aged 75 years and older and assessed the clinical efficacy and toxicity.
Article Synopsis
- - The ESMO Clinical Practice Guidelines for oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC) were updated into Pan-Asian adapted (PAGA) guidelines to better address the needs of Asian patients.
- - A panel of experts from multiple Asian oncological societies collaborated to create these guidelines, focusing on scientific evidence rather than local treatment practices or drug availability.
- - The guidelines aim to standardize the management of oncogene-addicted mNSCLC across Asia, while acknowledging regional differences in screening, treatment resources, and drug reimbursement policies.
Background: Immunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to immunosuppression and fibrosis in the TME. AMY109, a humanized anti-IL-8 monoclonal antibody, reduced fibrosis and decreased immunosuppressive cells in tumor tissue in animals.
View Article and Find Full Text PDFArticle Synopsis
- The study assesses the long-term outcomes of patients with nonsmall cell lung cancer (NSCLC) and high PD-L1 expression treated with either pembrolizumab alone (MONO) or in combination with chemotherapy (COMB).
- A total of 298 patients were observed, with COMB showing better overall survival (33.7 months) compared to MONO (17.2 months), although after adjusting for various factors, the advantage of COMB over MONO was not statistically significant.
- The findings suggest that while COMB may be beneficial in certain patients, both treatment options have similar discontinuation rates, indicating comparable tolerability.